US Patent

US8258132 — Pharmaceutical composition of a tachykinin receptor antagonist

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2027-09-26 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition of a tachykinin receptor antagonist for treating or preventing disorders such as depression, anxiety, inflammatory diseases, and emesis.

USPTO Abstract

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.

Drugs covered by this patent

Emend (APREPITANT) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-901`	—	Emend
`U-901`	—	Emend
`U-1743`	—	Emend
`U-1916`	—	Emend

Patent Metadata

Patent number: US8258132
Jurisdiction: US
Classification: Method of Use
Expires: 2027-09-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.